Navigation Links
Comparing combination therapies for advanced head and neck cancer shows no improvement
Date:3/7/2013

CHAPEL HILL, N.C. - Locally advanced squamous cell carcinoma of the head and neck is a potentially curable disease in nearly every patient at the time of diagnosis, yet despite the most aggressive efforts, up to 30-50 percent of patients may ultimately succumb to the disease. For diseases where outcomes are so uncertain, medical science frequently addresses the need by intensifying therapy. In the case of head and neck cancer, one of the great questions of the current day is whether or not addition of multiple drugs to radiation therapy is superior to the current standard of care therapy with one drug and radiation. In particular, physicians have wondered if the addition of the more tolerable targeted biologic therapy to chemotherapy results in improved patient outcomes. Unfortunately, the data suggests that it does not.

A team of scientists, including Neil Hayes, MD, MPH, from UNC Lineberger Comprehensive Cancer Center, report results of a clinical trial comparing treatments for this cancer, the seventh most common tumor type in the United States.

Standard therapy for SCCHN is a combination of the drug cisplatin and radiotherapy. The clinical trial compared this combination to the combination with the addition of a small-molecule inhibitor of the epidermal growth factor receptor called Erlotinib. EGFR is a therapeutic target for this type of cancer and at least one other EGFR is approved for multiple uses in the treatment of head and neck cancer, including in combination with radiation. To date, no data has been published on the use of EGFR inhibitors in combination with chemotherapy and radiation.. The goal of the current study was to determine if adding EGRF inhibition improved efficacy when combined with standard of care radiation. Unfortunately, it improved neither clinical response rate nor progression free survival.

Their results were published in the early online March 4, 2013 issue of the Journal of Clinical Oncology.

Dr. Hayes, associate professor of medicine, explains, "There has been great enthusiasm and some confusion about the combinations of chemotherapy and biologic therapy such as EGFR inhibitors in conjunction with radiation in the treatment of squamous cell carcinomas of the head and neck. For the moment, the data are clearly showing no added benefit. Since the study was initially designed, it is interesting to note that novel theories have emerged about subgroups of patients who might be more likely to benefit from the specific therapies under consideration. Future investigations will clearly rely more on patients selected by the molecular tumor characteristics."

Between December 2006 and October 2011, 204 patients with locally advanced SCCHN were recruited to the study. Participants were assigned to receive either cisplatin and radiotherapy or the same chemoradiotherapy with Erlotinab.


'/>"/>

Contact: Dianne Shaw
dgs@med.unc.edu
919-966-7834
University of North Carolina Health Care
Source:Eurekalert  

Related medicine news :

1. The ethics of access: Comparing 2 federal health care reform efforts
2. New drug combination could prevent head and neck cancer in high-risk patients
3. Mayo Clinic: 2-drug combination may slow deadly thyroid cancer
4. People with HIV hospitalized less often since combination antiretroviral drug therapy introduced
5. Combination of imaging exams improves Alzheimers diagnosis
6. Drug combination acts against aggressive chronic lymphocytic leukemia
7. Scientists test 5,000 combinations of 100 existing cancer drugs to find more effective treatments
8. Combination treatment may improve survival of breast cancer patients with brain metastases
9. Drug combination against NRAS-mutant melanoma discovered
10. Combination peptide therapies might offer more effective, less toxic cancer treatment
11. DNDi and Cipla to develop 4-in-1 pediatric antiretroviral drug combination
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Comparing combination therapies for advanced head and neck cancer shows no improvement
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... Coast Dental ... February is National Children’s Dental Health Month and family dentist Yvonne Dorrian, DMD, is ... at Coast Dental , located next to Target at 1207 North Peachtree Parkway ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... BantamPro L top-load case packer for pouches, bags, and flow wrapped products at ... help co-packers and specialty product manufacturers step up to semi-automatic or fully-automatic case ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... metro area, has selected the latest beneficiary of their ongoing community enrichment program. ... preventing bullying in area schools. Donations are now being accepted at: http://www.angelsanddoves.com/donate.html ...
(Date:2/8/2016)... ... ... Remember the old saying “rub some dirt on it”? Perhaps you should ... Bentonite Clay” the health benefits of integrating clay into a daily diet are numerous, ... former motivational speaker, Perry A~ has since dedicated her life to learning about the ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... greater than 50% lower incidence rate of type 2 diabetes in the GrassrootsHealth ... ”It is time to make a change in public health,” states Carole Baggerly, ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... COLUMBUS, Ohio , Feb. 8, 2016 /PRNewswire/ ... to introduce the PW Series Solvent Recycling Systems, ... series offers full integration with new and existing ... This integration produces consistently-fresh solvent through continuous recycling ... --> --> ...
(Date:2/8/2016)... , Feb. 8, 2016  Ventana Medical Systems, ... hundreds of the world,s top oncologists, pathologists, research ... the 12 th annual Tucson Symposium March ... theories and new outcomes in cancer research and ... lives. Thomas Grogan , annually draws ...
(Date:2/8/2016)... --  GS1 US will hold a series of ... Standards implementation to address the requirements of the U.S. ... rule. Scott Brown , director of ... director industry development, medical devices, GS1 US; and ... --> Scott Brown , director of ...
Breaking Medicine Technology: